Logo image of STSA

Satsuma Pharmaceuticals Inc (STSA) Stock Fundamental Analysis

NASDAQ:STSA - Nasdaq - US80405P1075 - Common Stock - Currency: USD

1.1  -0.01 (-0.9%)

After market: 1.07 -0.03 (-2.73%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to STSA. STSA was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of STSA is average, but there are quite some concerns on its profitability. STSA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

STSA had negative earnings in the past year.
STSA had a negative operating cash flow in the past year.
In the past 5 years STSA always reported negative net income.
In the past 5 years STSA always reported negative operating cash flow.
STSA Yearly Net Income VS EBIT VS OCF VS FCFSTSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

STSA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
STSA Yearly ROA, ROE, ROICSTSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 -2K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for STSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STSA Yearly Profit, Operating, Gross MarginsSTSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for STSA has been increased compared to 1 year ago.
STSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STSA Yearly Shares OutstandingSTSA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M
STSA Yearly Total Debt VS Total AssetsSTSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

STSA has an Altman-Z score of -6.49. This is a bad value and indicates that STSA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of STSA (-6.49) is worse than 67.28% of its industry peers.
STSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.49
ROIC/WACCN/A
WACCN/A
STSA Yearly LT Debt VS Equity VS FCFSTSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 7.44 indicates that STSA has no problem at all paying its short term obligations.
STSA's Current ratio of 7.44 is fine compared to the rest of the industry. STSA outperforms 71.89% of its industry peers.
STSA has a Quick Ratio of 7.44. This indicates that STSA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.44, STSA is in the better half of the industry, outperforming 73.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.44
Quick Ratio 7.44
STSA Yearly Current Assets VS Current LiabilitesSTSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

STSA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.92%.
EPS 1Y (TTM)-12.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, STSA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.03% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.57%
EPS Next 2Y31.44%
EPS Next 3Y22.81%
EPS Next 5Y15.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
STSA Yearly Revenue VS EstimatesSTSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M
STSA Yearly EPS VS EstimatesSTSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STSA. In the last year negative earnings were reported.
Also next year STSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STSA Price Earnings VS Forward Price EarningsSTSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STSA Per share dataSTSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as STSA's earnings are expected to grow with 22.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.44%
EPS Next 3Y22.81%

More info and screens

0

5. Dividend

5.1 Amount

STSA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Satsuma Pharmaceuticals Inc

NASDAQ:STSA (6/7/2023, 8:00:00 PM)

After market: 1.07 -0.03 (-2.73%)

1.1

-0.01 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-11 2023-05-11/amc
Earnings (Next)08-07 2023-08-07/amc
Inst Owners0.05%
Inst Owner Change0%
Ins Owners11.58%
Ins Owner Change0%
Market Cap36.47M
Analysts76.36
Price Target2.04 (85.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.2%
Min EPS beat(2)-89.37%
Max EPS beat(2)-3.02%
EPS beat(4)1
Avg EPS beat(4)-20.77%
Min EPS beat(4)-89.37%
Max EPS beat(4)13.37%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)-10.1%
EPS NQ rev (3m)-6.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-39.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.44
Quick Ratio 7.44
Altman-Z -6.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)921.09%
Cap/Depr(5y)764.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
EPS Next Y56.57%
EPS Next 2Y31.44%
EPS Next 3Y22.81%
EPS Next 5Y15.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.2%
EBIT Next 3Y24.32%
EBIT Next 5Y15.58%
FCF growth 1Y-11.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.53%
OCF growth 3YN/A
OCF growth 5YN/A